LFTD Partners (LIFD) AI Stock Analysis

16 Followers

Top Page

LFTD Partners

(OTC:LIFD)

45Neutral

LFTD Partners shows potential with revenue growth and a strong equity position. However, operational inefficiencies and negative profitability hinder its financial performance. Technical indicators show neutral market sentiment, while valuation raises concerns due to a negative P/E ratio and lack of dividends. Focus on improving profitability and managing operational costs to enhance overall stock performance.

LFTD Partners (LIFD) vs. S&P 500 (SPY)

Market Cap

$5.48M

Dividend YieldN/A

Average Volume (3M)1.52K

Price to Earnings (P/E)―

Beta (1Y)0.36

Revenue Growth-28.17%

EPS Growth-185.06%

CountryUS

Employees148

SectorHealthcare

Sector Strength41

IndustryDrug Manufacturers - Specialty & Generic

Share Statistics

EPS (TTM)-0.13

Shares Outstanding14,822,678

10 Day Avg. Volume2,752

30 Day Avg. Volume1,524

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)<0.01

Price to Sales (P/S)0.00

P/FCF Ratio<0.01

Enterprise Value/Market Cap372.47K

Enterprise Value/Revenue0.22

Enterprise Value/Gross Profit0.92

Enterprise Value/Ebitda-6.22

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

LFTD Partners Business Overview & Revenue Model

Company DescriptionLFTD Partners Inc., through its subsidiary, Lifted Made, manufactures and sells psychedelic products under its Silly Shruum brand and hemp-derived cannabinoid products under its Urb Finest Flowers brand. The company was formerly known as Acquired Sales Corp. and changed its name to LFTD Partners Inc. in September 2021. LFTD Partners Inc. was incorporated in 1986 and is headquartered in Jacksonville, Florida.

How the Company Makes MoneyLFTD Partners generates revenue primarily through the sale of its cannabis and hemp-derived products. The company earns money by developing and marketing a variety of consumer goods that cater to the cannabis market, including edibles, tinctures, vape products, and other infused offerings. Significant partnerships and collaborations with manufacturers and distributors enable LFTD Partners to expand its market reach and enhance its product distribution channels. Additionally, the company may engage in strategic acquisitions to bolster its product lineup and enhance its competitive position in the industry.

LFTD Partners Financial Statement Overview

Summary

LFTD Partners demonstrates growth in revenue and maintains a strong equity position. However, the company faces challenges with operational inefficiencies impacting profitability. Cash flow improvements are promising, but historical volatility calls for careful monitoring. To enhance financial health, focus on improving profit margins and managing liabilities effectively.

Income Statement

Neutral

LFTD Partners shows a mixed trajectory in its income statement. While revenue has grown substantially in the TTM period, gross profit margins remain healthy but are offset by negative EBIT and net profit margins, indicating operational inefficiencies and high costs. Revenue growth is a positive indicator, but profitability metrics need improvements for a stronger financial standing.

Balance Sheet

Neutral

The balance sheet highlights a strong equity position with a relatively low debt-to-equity ratio, reflecting financial stability. However, there is a substantial increase in total liabilities in the TTM period that could pose risks if not managed. The equity ratio remains healthy, indicating a significant portion of assets financed by equity.

Cash Flow

Neutral

Cash flow analysis shows positive free cash flow in the TTM period, a significant improvement from previous years. Operating cash flow covers net income well, suggesting efficient cash management, but the company has experienced fluctuations in free cash flow historically, indicating potential volatility.

TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
9.12T	37.33M	51.61M	57.42M	31.66M	5.34M
	Gross Profit
2.22T	12.54M	19.70M	20.99M	15.94M	1.94M
	EBIT
-1.10T	-773.46K	2.41M	9.81M	7.78M	-1.34M
	EBITDA
-328.39B	-1.49M	3.35M	10.31M	7.40M	-1.45M
	Net Income Common Stockholders
-303.04B	-1.86M	2.16M	7.20M	5.80M	-1.60M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.28T	2.15M	4.36M	3.72M	1.60M	439.08K
	Total Assets
47.76T	47.32M	51.35M	41.13M	39.42M	27.83M
	Total Debt
4.32T	4.51M	4.49M	1.86M	1.34M	3.91M
	Net Debt
2.04T	2.36M	130.37K	-1.67M	-263.84K	3.47M
	Total Liabilities
10.56T	9.81M	12.53M	6.59M	11.96M	6.21M
	Stockholders Equity
37.20T	37.50M	38.82M	34.54M	27.46M	21.62M
Cash Flow		Free Cash Flow
274.60B	-1.27M	-150.74K	2.12M	5.25M	-408.17K
	Operating Cash Flow
351.75B	-960.07K	638.92K	3.04M	5.62M	-338.04K
	Investing Cash Flow
-77.15B	-479.57K	-2.52M	-916.12K	-446.65K	-3.51M
	Financing Cash Flow
-141.59B	-770.95K	3.70M	-193.42K	-4.01M	-98.00K

LFTD Partners Technical Analysis

Technical Analysis Sentiment

Positive

Last Price0.37

Price Trends

50DMA

0.36

Positive

100DMA

0.39

Negative

200DMA

0.50

Negative

Market Momentum

MACD

>-0.01

Positive

RSI

51.18

Neutral

STOCH

70.43

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIFD, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.36, and below the 200-day MA of 0.50, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.18 is Neutral, neither overbought nor oversold. The STOCH value of 70.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LIFD.

LFTD Partners Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
LIFD	45 Neutral	$5.48M	―	-2.72%	―	-28.17%	-185.06%
XBIO	43 Neutral	$4.56M	―	-53.16%	―	-1.56%	5.01%
KZIA	31 Underperform	$4.07M	―	-2639.52%	―	―	19.58%
OGEN	29 Underperform	$4.27M	―	-748.05%	―	-100.00%	76.55%
ALLR	28 Underperform	$16.14M	―	-383.73%	―	―	99.43%
CHEK	26 Underperform	$5.15M	―	-74.17%	―	―	―

* Healthcare Sector Average

Performance Comparison

LIFD

LFTD Partners

0.37

-0.55

-59.78%

KZIA

Kazia Therapeutics

3.64

-10.45

-74.17%

CHEK

Check-Cap

0.88

-1.34

-60.36%

OGEN

Oragenics

0.20

-2.84

-93.42%

XBIO

Xenetic Biosciences

2.96

-0.76

-20.43%

ALLR

Allarity Therapeutics

1.07

-16.31

-93.84%

LFTD Partners Earnings Call Summary

Earnings Call Date:Mar 27, 2025

(Q3-2024)

% Change Since: 15.62%|

Next Earnings Date:May 20, 2025

Earnings Call Sentiment Negative

The earnings call presented a mixed picture with notable efforts to launch new products and reduce expenses, but these were overshadowed by significant revenue declines, operating losses, and challenges in receivables. The competitive and regulatory environment continues to pose significant challenges to LFTD Partners.

Q3-2024 Updates

Positive Updates

Launch of New Product Line

Launched the newest iteration of the flagship brand, Urb, featuring a Fly High theme with major initiatives to increase direct-to-retailer and direct-to-consumer online sales.

Expense Reduction Achievements

Reduced payroll expenses by 8% from Q1 '24 to Q2 '24 and another 8% from Q2 to Q3 '24. Professional fee expenses down 40% from Q1 to Q2 '24 and another 33% from Q2 to Q3.

Gross Margin Improvement

Excluding the effect of written-off inventory, gross margin as a percentage of net sales improved to 47% compared to 38%.

Negative Updates

Significant Revenue Decline

Consolidated net sales were $8.6 million, down 34% due to regulatory challenges, economic pressure on consumers, and increased competition.

Operating Loss

Reported an operating loss of $141,000 compared to operating income of $659,000 in the previous year.

Net Loss Reported

Net loss was $194,000 or $0.01 per share compared to net income of $617,000 or $0.04 per share.

Challenges in Receivables

Faced $864,000 of bad debt expense due to delayed payments from certain customers, impacting net receivables, net income, and earnings per share.

Company Guidance

During the LFTD Partners' Q3 2024 earnings call, several key metrics and strategic initiatives were discussed to address the current challenges and future prospects of the company. The company's consolidated net sales were reported at $8.6 million, a decline of 34% compared to the previous year, attributed to regulatory challenges and increased competition in the hemp-derived cannabinoid market. Despite these headwinds, the company has been proactive in reducing payroll expenses by 8% from Q1 to Q2 and another 8% from Q2 to Q3, along with a 40% reduction in professional fees from Q1 to Q2 and a further 33% reduction from Q2 to Q3. Furthermore, the company has reduced its CapEx from $747,000 in the previous year to $310,000 year-to-date. The operating loss for the quarter was $141,000, contrasting with an operating income of $659,000 in the same quarter of the previous year. The net loss was reported at $194,000 or $0.01 per share, compared to a net income of $617,000 or $0.04 per share in Q3 2023. The company's current ratio improved to 2.64, reflecting a focus on maintaining financial stability amidst industry challenges.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.